

1 Genome sequencing reveals the impact of non-canonical exon inclusions 2 in rare genetic disease

3

4 Georgia Pitsava¹, Megan Hawley², Light Auriga¹, Ivan de Dios¹, Arthur Ko³, Sofia Marmolejos³, Miguel
5 Almalvez¹, Ingrid Chen², Kaylee Scozzaro², Jianhua Zhao², Rebekah Barrick⁶, Nicholas Ah Mew^{3,4},
6 Vincent A. Fusaro¹, Jonathan LoTempio¹, Matthew Taylor⁷, Luisa Mestroni⁷, Sharon Graw⁷, Dianna
7 Milewicz⁸, Dongchuan Guo⁸, David R. Murdock⁸, Kinga M. Bujakowska⁹, UCI-GREGoR Consortium,
8 Changrui Xiao⁵, Emmanuèle C. Délot¹, Seth I. Berger^{3,4}, Eric Vilain¹

9

10

11 ¹Institute for Clinical and Translational Science, University of California, Irvine, CA, USA

12 ²Labcorp Genetics Inc, Burlington, North Carolina, USA

13 ³Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA

14 ⁴Division of Genetics and Metabolism, Children's National Hospital, Washington, DC, USA

15 ⁵Department of Neurology, University of California, Irvine, CA, USA

16 ⁶Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange, CA 92868,
17 USA

18 ⁷Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical
19 Campus, Aurora, CO, USA

20 ⁸Division of Medical Genetics, University of Texas Health Science Center at Houston (UTHealth)
21 McGovern Medical School, Houston, Texas, USA

22 ⁹Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary,
23 Harvard Medical School, Boston, MA, USA

24

25

26 Correspondence: sberger@childrensnational.org

27

28

29

30

31

32

33 Abstract

34

35 Introduction

36 Advancements in sequencing technologies have significantly improved clinical genetic testing,
37 yet the diagnostic yield remains around 30-40%. Emerging sequencing technologies are now
38 being deployed in the clinical setting to address the remaining diagnostic gap.

39 Methods

40 We tested whether short-read genome sequencing could increase diagnostic yield in individuals
41 enrolled into the UCI-GREGoR research study, who had suspected Mendelian conditions and
42 prior inconclusive clinical genetic testing. Two other collaborative research cohorts, focused on
43 aortopathy and dilated cardiomyopathy, consisted of individuals who were undiagnosed but had
44 not undergone harmonized prior testing.

45 Results

46 We sequenced 353 families (754 participants) and found a molecular diagnosis in 54 (15.3%) of
47 them. Of these diagnoses, 55.5% were previously missed because the causative variants were in
48 regions not interrogated by the original testing. In 9 cases, they were deep intronic variants, 5 of
49 which led to abnormal splicing and cryptic exon inclusion, as directly shown by RNA
50 sequencing. All 5 of these variants had inconclusive spliceAI scores. In 26% of newly diagnosed
51 cases, the causal variant could have been detected by exome sequencing reanalysis.

52 Conclusion

53 Genome sequencing overcomes multiple limitations of clinical genetic testing, such as inability
54 to call intronic variants and technical limitations. Our findings highlight cryptic exon inclusion as
55 a common mechanism via which deep intronic variants cause Mendelian disease. However, they
56 also reinforce that reanalysis of exome datasets can be a fruitful approach.

57

58

59

60

61

62 Keywords: genome sequencing, RNA sequencing, rare disease, intronic variants, cryptic exon

63

64

65

66 **Introduction**

67 The widespread application of clinical genetic testing has tremendously increased the rate at which
68 rare genetic diseases are being diagnosed and new gene-disease associations are identified. Despite
69 this progress, the diagnostic yield of clinical genetic testing remains 30-40% [1, 2]. There are
70 several reasons for this plateau. For many conditions, the causal genes are still unidentified. Even
71 for conditions with known causal genes, interpreting the clinical significance of variants can be
72 challenging. This is because there are a large number of variants with insufficient information
73 pertinent to their pathogenicity, known as variants of unknown significance (VUS). In addition,
74 technical limitations of commonly offered clinical tests can result in missed variants, for example
75 in regions that are not represented in exome sequencing such as deep intronic and untranslated
76 regions. Epigenetic factors that affect gene expression but are not interrogated by standard testing
77 potentially add to the complexity.

78 Molecular sequencing technologies not traditionally used in the clinical setting are now being
79 deployed in order to overcome these challenges. These include the increasing use of genome
80 sequencing (GS) as well as RNA sequencing. The latter can be especially useful for directly
81 evaluating the functional consequences of intronic variants and variants in splice regions, since
82 despite advances in computational predictors of splicing disruption (such as SpliceAI and Pangolin
83 [3, 4]) it often remains difficult to determine if these variants are pathogenic or not.

84 The University of California, Irvine (UCI) - GREGoR site, part of the GREGoR (Genomics
85 Research to Elucidate the Genetics of Rare Diseases) Consortium, has been evaluating the
86 diagnostic utility of these newer approaches. Our study has been enrolling participants whose
87 clinical presentation strongly suggests a genetic cause, but who remain without a molecular
88 diagnosis, despite having undergone conventional genetic testing (gene panels, chromosomal
89 microarray, exome sequencing - ES).

90 Here, we describe our center's experience from short-read GS of a cohort of 353 such families
91 (754 participants). To help disambiguate previously or newly detected variants (VUS or single
92 heterozygous pathogenic variants in recessive disease genes), we deployed additional methods,
93 including RNA sequencing. We also provide an overview of our cohort and focus on lessons
94 learned from informative, successfully solved cases.

95

96 **Methods**

97 *Participants*

98 The Mendelian Genomics Research Center was launched in 2021, between Children's National
99 Hospital, Invitae, and more recently UCI. The study was approved by the Institutional Review
100 Board (IRB) of Children's National Hospital (Pro00015852). Study participants included
101 probands with a suspected Mendelian condition and prior non-diagnostic clinical testing, such as
102 gene panels, chromosomal microarray, or ES. Testing on additional family members was
103 performed when available. Individuals were enrolled over a three-year period, from July 2021 to
104 April 2024, through referrals by physicians and collaborators, or self-referral via our website

105 (<https://research.childrensnational.org/labs/pediatric-mendelian-genomics-research-center>).
106 Written informed consent was available in both English and Spanish and was obtained for all
107 families by study staff or through a study-specific automated chatbot [5]. Workflows for remote
108 enrollment and sample collection were established, eliminating the need for participants to travel.
109 Following consent, buccal swabs and/or peripheral blood samples were collected from probands
110 and their relevant available family members. Some participants provided clinically generated
111 genome data for reanalysis [6]. In addition, our study population involved two collaborative
112 cohorts, one focusing on aortopathy and another on dilated cardiomyopathy; for these their prior
113 genetic testing may not have been as comprehensive or well documented. Phenotypic categories
114 are described in **Table 1**.

115 *Short-read Genome Sequencing*

116 Blood and buccal samples were sent to Invitae® laboratories where they were processed and
117 underwent genome sequencing using Illumina NovaSeq 6000. Sequencing files were subsequently
118 aligned to the hg38 human genome assembly with bwa-mem using soft clipping enabled for
119 supplementary alignments (-Y), processed at 120,000,000 input bases per batch for reproducibility
120 (-K) [7] and genotyped using Google DeepVariant [8]. Structural variant calling was performed
121 with Illumina Manta [9]. Alignments and variant call files are available on the NHGRI Analysis
122 Visualization and Informatics Lab-space (AnVIL; [AnVIL Portal](#)) on the GREGoR Consortium
123 workspace.

124 *Short-read RNA sequencing*

125 Blood samples were preserved in PAXgene tubes processed with the WatchMaker Genomics RNA
126 library prep kit with the Polaris depletion module to create stranded and ribosomal/globin-depleted
127 libraries. They then underwent RNA sequencing using the Illumina NovaSeq 6000 S4 flowcells
128 generating 100-200 million 150-bp read pairs. Reads were aligned to hg38 using STAR (v2.7.10a)
129 [10] with the GENCODEv41 annotation. We employed the basic two-pass mode and allowed up
130 to 3 mismatches and a minimum aligned length of 100 bp. Alignments were visualized using
131 integrative genomics viewer (IGV) [11-14]. Alignments are available on AnVIL ([AnVIL Portal](#)).

132 *Mini gene assays*

133 A minigene splicing assay was performed using a mini-gene split Green Fluorescent Protein (GFP)
134 construct [15], in which N- and C-terminal parts of the *GFP* gene were separated by *SMN1* introns
135 7 and 8 (NM_000344). Reference and mutated gene fragments containing 1000 bp of *DBT* intron
136 10 surrounding the c.1282-4218G>A variant flanked with 30 bp vector homology arms were
137 synthesized (TWIST Bioscience, USA) and cloned into the mini-gene construct (Gibson Assembly
138 Master Mix, New England Biolabs). After Sanger sequencing verification of all constructs, they
139 were transfected into HEK293 cells (Lipofectamine 3000, Thermo Fisher Scientific). Forty-eight
140 hours post transfection, total RNA was extracted from the transfected cells (RNAeasy Mini Kit,
141 Qiagen) and cDNA was generated using random hexamer primers (SuperScript IV Synthesis Kit,
142 Thermo Fisher Scientific). Subsequently, the minigene transcripts were amplified from the cDNA
143 using primers specific to the split *GFP* fragments (F: 5'-
144 CACACTGGTGACAACATTTACATAC-3'; R: 5'-GAAATCGTGCTGTTTCATGTGATC-3').

145 The PCR products were column-purified (DNA Clean & Concentrator-5, Zymo Research) and
146 analyzed with next-generation amplicon sequencing (MiSeq, Illumina, OGI Genomics Core). The
147 splicing pattern analysis was performed by aligning the sequence reads to the hybrid reference of
148 the split *GFP* construct containing the *DBT* intron 10 (STAR Aligner) [16] and visualizing the
149 reads in (IGV) [11-14]. The same process was followed to test the effect of the *HFE* VUS found
150 in participant PMGRC-124-124-0.

151 *Variant prioritization and analysis*

152 Phenotypic data for probands was collected via a manual review of electronic medical records or
153 provided by collaborating researchers. The phenotypes of each proband were converted to Human
154 Phenotype Ontology (HPO) terms.

155 Variants were reviewed by expert curators using the MOON™ software. MOON implements a
156 natural language processing approach to prioritize variants in genes that are likely to be related to
157 an individual's phenotype based on published literature [17, 18]. Cases were reviewed with the
158 goal of identifying pathogenic, likely pathogenic, and VUS in known disease genes consistent with
159 the phenotype of the proband. In addition to sequence and structural variants prioritized by
160 MOON, rare sequence variants in the following categories were reviewed: those expected to result
161 in loss of function, *de novo* variants, compound heterozygous or homozygous variants,
162 hemizygous variants, variants classified as likely pathogenic or pathogenic in ClinVar, and
163 variants in genes associated with conditions with a high clinical overlap for the patient.

164 Cases were considered “solved” when a disease-causing variant or multiple disease-causing
165 variants in a gene associated with a condition consistent with the phenotype of the proband were
166 detected. The number and phase of variants needed to be consistent with the inheritance pattern of
167 the condition. For example, a single likely pathogenic or pathogenic variant in an autosomal
168 dominant condition or biallelic likely pathogenic or pathogenic variants in an autosomal recessive
169 condition were needed for a case to be considered “solved”. Cases were considered “probably
170 solved” when one or more of the variants were classified as a VUS but there was a strong
171 phenotypic overlap with the clinical presentation of the patient. Cases were considered “partially
172 solved” if likely pathogenic or pathogenic variants consistent with the inheritance pattern of the
173 condition were detected, but the result only explained part of the proband's phenotype.

174 Finally, we note that analysis is ongoing; the data reported on this manuscript are as of October 1,
175 2024.

176

177 **Results**

178 *Genome Sequencing leads to a molecular diagnosis in 15.3% of previously unsolved cases*

179 A total of 353 families underwent GS during the designated period; demographic information is
180 shown in **Figures 1a and 1b**. Our study included several different family structures; 41.9%
181 (n=148) were proband-only cases, 13.3% (n=47) were duos or duos plus another family member
182 (duo+), 43.3% (n =153) were trios or trios with another family member (trio+) and 1.4% (n=5)

183 consisted of other family combinations (**Figure 2a**). This accounts for a total of 754 genomes
184 analyzed.

185 A genetic diagnosis was found in 54 (15.3%) cases (solved/probably solved; Supplemental Table
186 1). As expected, the diagnostic yield was higher in trios/trios+ compared to duos/duos + and
187 proband-only families (21% vs 13% and 10%; **Figure 2b**). This difference was statistically
188 significant ($p = 0.03$, chi-square test).

189 In addition, 6 cases (1.7%) were partially solved; that is, the identified variant could explain part,
190 but not the entirety, of the individual's phenotype. Furthermore, we found a candidate variant in
191 approximately 9% of the cases that remained unsolved (27 out of the 299; Supplemental Table 2).

192 To better understand why the diagnosis was previously missed in the 54 solved/probably solved
193 cases, we examined the type of prior testing these participants had undergone (**Figure 3a**). In 26%
194 (14 out of 54) of solved cases, the causal variant had been identified by initial testing but was not
195 reported either because the gene-phenotype association was unknown at the time of that testing or
196 because the variant was not classified as pathogenic at the time (**Figure 3b**). Below, we focus on
197 cases where initial testing did not interrogate the genomic region harboring the causative variant.

198 *Diagnoses in uninterrogated regions of original testing highlight cryptic exon inclusion as a*
199 *common mechanism by which deep intronic variants cause disease*

200 In the majority of solved/probably solved cases (55.5%; 30 out of 54 cases), the diagnosis was
201 missed before because the original testing method was unable to call variants in the region
202 harboring the causative variant. For example, there were 13 cases where panel testing did not
203 include the causal gene, and 13 cases where the causative variant was non-coding. In one case, a
204 synonymous coding-region variant was predicted by spliceAI to lead to intron retention in *HFE*.
205 This intron retention event leading to a stop-gain was confirmed using a mini gene assay
206 (Supplemental Figure 1).

207 With respect to non-coding causative variants, these were deep intronic in 9 cases. In five of those,
208 the causative variant altered the canonical splicing pattern via the inclusion of a cryptic exon
209 (**Table 2**). Variant pathogenicity was revealed by RNAseq, which directly demonstrated the effect
210 at the transcript level. For example, one case was due to an intronic variant in *PEXI*, in a patient
211 with a known biochemical diagnosis of Zellweger Spectrum Disorder and a carrier of a
212 heterozygous known pathogenic variant in *PEXI*. The abnormal cryptic exon inclusion was
213 revealed by RNAseq (Supplemental Figure 2). Another example was a newborn female who was
214 biochemically diagnosed with thiamine-responsive maple syrup urine disease (MSUD) based on
215 the same diagnosis in her sister. However, all prior genetic testing (panel testing of 9 genes, *ASL*
216 single-gene testing, and ES) was negative. GS revealed a homozygous deep (-4230) intronic single
217 nucleotide variant predicted to lead to aberrant splicing of *DBT*, a gene known to cause MSUD
218 type II (OMIM# 620699), which can sometimes be thiamine-responsive. RNAseq confirmed the
219 cryptic exon inclusion, establishing the molecular diagnosis (**Figure 4a**). This variant was also
220 confirmed by minigene assay (**Figure 4b-e**). In another case we found a deep intronic variant in a
221 case of Coffin-Siris, which we validated by epismature in long-read sequencing [19].

222 We found that, in all five cases with a cryptic exon inclusion, both the acceptor gain and the donor
223 gain spliceAI scores fell within a range generally considered inconclusive with regards to impact
224 on splicing (range 0.16 - 0.43 for acceptor gain scores; 0.19 - 0.55 for donor gain scores). This
225 observation, while preliminary, suggests that the combination of such acceptor gain and donor gain
226 scores may be a marker for variants leading to this splicing alteration. Of note, commonly used
227 pre-calculated spliceAI scores limit their search to 50 bp from the variant, and therefore in each of
228 these examples the new splice acceptor would not have been detected with pre-calculated spliceAI
229 scores alone. It required a direct calculation of a spliceAI score with a search of at least 500 bp
230 from the variant. Pangolin scores were generally higher than spliceAI scores.

231 Four additional cases harbored variants in the spliceosomal non-coding RNA *RNU4-2* and
232 contributed to the discovery of ReNU syndrome (OMIM#620851) [20]. Variants in this gene
233 represent a new, surprisingly common etiology of neurodevelopmental disorders, explaining
234 approximately 0.4% of such cases.

235 Finally, an informative example in which the causal variant was missed due to variant filtering
236 parameters driven by limitations of ES was a woman in her 30s with glomuvenous malformations,
237 conductive hearing loss, and midline malformations. Previous testing included a cancer 38-gene
238 panel, *GLA* single-gene testing, ES, and mitochondrial testing; all were negative. GS revealed a
239 known pathogenic exonic frameshift variant in *GLMN* (Glomuvenous Malformation Syndrome;
240 OMIM#138000). Upon review of the previous clinical ES, we discovered that this same variant
241 was detectable in the original data. However, the variant had not been reported as the exon was
242 excluded from the lab's clinically validated regions due to a propensity for sequencing artifacts in
243 this exon. Clinicians ordering clinical exome sequencing may not be aware of the coverage
244 limitations of clinically relevant genes or exons important for the testing indication.

245 *Detection of structural variants*

246 We also identified structural variants not detected by previous testing. This includes a complex
247 rearrangement of *OCA2* with deep intronic breakpoints [6] and deletion of the first exon of
248 *CREBBP* in a child with features of Rubinstein-Taybi syndrome 1 (OMIM#180849) and previous
249 negative ES. It is important to note that while ES has made strides in detection of structural
250 variants, copy-neutral variants and single-exon deletions may still not be detected.

251 *Syndromic phenotypes had the highest solve rate*

252 When examining the solve rate separately for each phenotypic category, the largest number of
253 diagnoses were obtained in individuals with syndromic phenotypes (32 solved cases out of 128
254 total cases; 25%), while the solve rate in non-syndromic cases was 9.8% (**Figure 5A**). When
255 further stratifying non-syndromic cases according to the affected organ system (**Figure 5B**),
256 individuals whose phenotype was categorized as 'Cardiovascular' were the most likely to receive
257 a diagnosis in our entire cohort (7 out of 19, 36.8 %). All but one of these individuals who received
258 a diagnosis were affected by dilated cardiomyopathy and were part of a legacy cohort. The genes
259 we found were not known to be associated with dilated cardiomyopathy at the time of testing,
260 which explains why they were initially missed.

261

262 **Discussion**

263 Our study provides a characterization of the potential of short-read GS, combined with other
264 confirmatory analyses such as RNAseq, to yield genetic diagnoses for previously undiagnosed
265 cases. GS provides a molecular diagnostic advantage over ES in that it can detect variants in
266 regions not interrogated by ES such as introns or non-coding genes, while RNAseq can assist in
267 establishing the pathogenicity of intronic splice-altering variants by directly demonstrating the
268 impact on the RNA product. Here, using a combination of GS and RNAseq we discovered cryptic
269 exon inclusion as a common (among intronic variants) molecular mechanism with a loss-of-
270 function impact via perturbed splicing.

271 Regarding causative variants in non-protein coding genes, while some examples of disease-
272 causing non-coding RNAs were previously known, this number is now expanding thanks to the
273 implementation of GS. Recently discovered examples include the aforementioned *RNU4-2*,
274 encoding the U4 small nuclear RNA (snRNA) component of the major spliceosome [20, 21], and
275 the long non-coding RNA *CHASERR*, which was shown to cause a novel syndromic
276 neurodevelopmental disorder [22].

277 Going forward, we envision that improvements in our ability to evaluate the impact of variants in
278 regions traditionally missed by conventional genetic testing will continue to increase the diagnostic
279 yield of GS. It is important to recognize, however, that in some cases it may be cost-effective to
280 reanalyze ES data instead of resorting to GS, especially given advances in variant interpretation
281 driven by better predictive models of variant effects and an expanded understanding of tolerated
282 genetic variation. Indeed, many causal variants in our study could have been detected by a
283 reanalysis of ES data, using new information provided by variant reclassification or improved
284 analytic pipelines; a finding that is in alignment with results from previous studies [23-25]. In
285 addition, testing of other family members can also aid in variant reinterpretation by showing if a
286 variant is *de novo* or if it segregates with the phenotype in the family. Finally, we speculate that
287 newer long-read sequencing technologies will help further close the diagnostic gap by capturing
288 variants not captured by short-read technologies such as certain structural variants and repeat
289 expansions [26].

290

291

292 **Data Availability**

293 Data available in the GREGoR workspace in AnVIL ([AnVIL Portal](#)).

294

295 **Funding Statement**

296 The study was supported by the National Institutes of Health grant U01HG011745, as part of the
297 GREGoR Consortium. KMB was supported by the GREGoR Consortium Research Grant from

298 the GREGoR Data Coordinating Center [U24HG011746]; National Eye Institute [R01EY035717
299 (KMB) and P30EY014104 (MEEI core support)], Iraty Award 2023 (KMB), Lions Foundation
300 (KMB) and the Research to Prevent Blindness Unrestricted Grant (KMB).

301

302 Disclosures/Conflict of interest

303 M.H, J.Z. and K.S. are currently employees of Labcorp Genetics Inc, formerly known as Invitae
304 Corp, I.C. is a former employee of Invitae Corp. All other authors declare no conflicts of interest.

305

306 Acknowledgements

307 We thank the participants and referring physicians for participating in this study.

308

309 Ethics Declaration

310 This study was approved by the Children’s National Hospital Institutional Review Board (IRB)
311 under protocol Pro00015852. Informed consent was obtained from all participants as required by
312 the IRB.

313

314

315

316

317

318

319

320

321

322

323

324

325

326 Table 1. Definitions of Phenotypic Categories

Multisystem Syndromic Disorders	Proband presenting with symptoms affecting multiple organ systems, often accompanied by distinctive facial features.
Non-syndromic Disorders	Proband with conditions that predominantly affect a single organ system, without significant involvement of other systems.
Subcategories	
Neurodevelopmental Disorders	Probands exhibiting conditions that primarily affect the development and function of the nervous system, including the brain, spinal cord, and peripheral nerves. This category encompasses disorders impacting cognitive function, behavior, motor skills, and neurological processes.
Cardiovascular Disorders	Proband with primary involvement of the heart and blood vessels, such as structural heart defects, cardiomyopathies, arrhythmias, and vascular diseases.
Connective Tissue & Skeletal Disorders	Proband with symptoms affecting bones, joints, and connective tissues such as skin, tendons, and ligaments.
Other	Proband who do not clearly fit any of the aforementioned categories.

327

328

329

330

331

332

333

334

335

336

337 Table 2. Participants with cryptic exon inclusion.

Participant ID	Variant	Gene	SpliceAI score		Distance to variant		Pangolin score (Gain)
			Acceptor	Donor	New Acceptor	New Donor	
PMGRC-146-146-0	c.3235+700C>G	<i>ARID1B</i>	0.31	0.19	-143 bp	-5 bp	0.54
PMGRC-220-220-0	c.1390-515_1390-499del	<i>HADHB</i>	0.27	0.27	-85 bp	27 bp	0.35
PMGRC-332-332-0	c.789+973C>G	<i>CRPPA</i>	0.43	0.55	118 bp	5 bp	0.46
PMGRC-403-403-0	c.1359+601A>G	<i>PEXI</i>	0.30	0.54	168 bp	0 bp	0.36
PMGRC-658-658-0	c.1282-4218G>A	<i>DBT</i>	0.16	0.20	161 bp	3 bp	0.66

338 SpliceAI scores were calculated using the spliceAI lookup tool with a maximum distance of 500 bp.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358 Supplemental Table 1. Solved/Probable solved cases

Participant ID	Phenotypic Category	Gene	Variant	Patient Phenotype	Reason diagnosis was missed on previous testing	Associated Disorder (OMIM)
PMGRC-13-13-0	Syndromic	<i>PTHLH</i>	c.4C>T, p.Gln2*	Pseudohypoparathyroidism, Chiari 1 malformation, shortened metacarpals	Limited Original Testing	Brachydactyly, type E2 (#613382)
PMGRC-32-32-0	Other	<i>FLG</i>	c.1297_1298del, p.Asp433fs c.2282_2285del, p.Ser761fs	Eczematoid dermatitis, numerous arcuate plaques with erythematous border, perivascular and interstitial dermatitis with neutrophils on biopsy, ichthyosiform xerosis	Limited Original Testing	Ichthyosis vulgaris (#146700)
PMGRC-43-43-0	Syndromic	<i>HECTD1</i>	c.2082C>G, p.Phe694Leu	Hypotonia, oral dysphagia, macrocephaly, autism spectrum disorder, somatic overgrowth syndrome, hypothalamic obesity, tube feeding, esotropia, stereotypic movements, abnormal brain MRI, dysmorphic facial features	New Information/Reclassification/Candidate gene now linked to syndrome	HECTD1-neurodevelopmental disorder (under review)
PMGRC-46-46-0	Syndromic	<i>PPP1R3F</i>	c.554_555del, p.His185fs*66	Hypotonia, tube feeding, autism spectrum disorder, speech/language delays, developmental delay	New Information/Reclassification/Candidate gene now linked to syndrome	X-linked PPP1R3F neurodevelopmental disorder [27]
PMGRC-88-88-0	Syndromic	<i>NARS2</i>	c.749G>A, p.Arg250Gln	Critically ill neonate with multisystemic disease. A few months later, new findings of interstitial lung disease and refractory seizures	Limited Original Testing	Combined oxidative phosphorylation deficiency 24 (#616239)
PMGRC-101-101-0	Syndromic	<i>CBL</i>	c.1259G>A, p.Arg420Gln	Hemihypertrophy, nystagmus, club foot	Previously known	Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (#613563)
PMGRC-114-114-0	Connective tissue & Musculoskeletal disorders	<i>ACAN</i>	c.4753del, p.Asp1585fs c.757+4A>G	Severe scoliosis, spondyloepimetaphyseal dysplasia, genu valgum, short stature	Previously known	Spondyloepimetaphyseal dysplasia, aggrecan type (#612813)

PMGRC-124-124-0	Syndromic	<i>HFE</i>	c.187C>G, p.His63Asp c.892G>A, p.Glu298Lys	Liver disease, hyperammonemia, encephalopathy, hyperbilirubinemia	Limited Original Testing	Hemochromatosis, type 1 (#235200)
PMGRC-146-146-0	Syndromic	<i>ARID1B</i>	c.3235+700C>G	Developmental delay, gross motor delay, abnormal brain MRI, mixed receptive-expressive language disorder, dysmorphic facial features	Limited Original Testing	Coffin-Siris syndrome 1 (#135900)
PMGRC-148-148-0	Syndromic	<i>RNU4-2</i>	n.64_65insT	Hypotonia, global developmental delay, speech delay, febrile seizures, optic nerve hypoplasia, tube feeding, dysmorphic facial features	Limited Original Testing	ReNU syndrome (#620851)
PMGRC-151-151-0	Syndromic	<i>GLMN</i>	c.157_161del, p.Glu52_Lys53insTer	Clinical diagnosis of glomuvenous malformations	Limited Original Testing	Glomuvenous malformations (#138000)
PMGRC-158-158-0	Syndromic	<i>COQ2</i>	c.421G>C, p.Val141Leu c.138dup, p.Ala47fs	Retinal atrophy, horseshoe kidney, nephrotic syndrome	New Information/Reclassification	Coenzyme Q10 deficiency, primary, 1 (#607426)
PMGRC-170-170-0	Neurodevelopmental	<i>GRIA4</i>	c.1643G>C, p.Trp548Ser	Hypotonia, feeding difficulties, global developmental delays of motor and language skills, microcephaly, delayed visual attention, abnormal brain MRI	New Information/Reclassification	Neurodevelopmental disorder with or without seizures and gait abnormalities (#617864)
PMGRC-175-175-0	Syndromic	<i>PTPN11</i>	c.1510A>G, p.Met504Val	Pulmonary valve stenosis, toe syndactyly, widely spaced nipples	Previously Known	Noonan syndrome 1 (#163950)
PMGRC-176-176-0	Syndromic	<i>SCN8A</i>	c.2549G>A, p.Arg850Gln	Refractory seizures, epileptic encephalopathy, infantile spasms, global developmental delay, hypotonia, tube feeding, respiratory insufficiency, hypotonia	Previously Known	Developmental and epileptic encephalopathy 13 (#614558)
PMGRC-178-178-0	Neurodevelopmental	<i>CHD1</i>	c.1010C>T, p.Thr337Ile	Motor delay, hypotonia, stereotypic behaviors, autism spectrum disorder	New Information/Reclassification	Pilarowski-Bjornsson syndrome (#617682)

PMGRC-204-204-0	Neurodevelopmental	<i>FBXO31</i>	c.1000G>A, p.Asp334Asn	Abnormal brain MRI, gross motor delay, speech delay, hypertonia, lower extremity spasticity, esotropia, mixed receptive-expressive language disorder	New Information/Reclassification	FBXO31-related spastic-dystonic cerebral palsy syndrome [28]
PMGRC-205-205-0	Syndromic	<i>SLC6A8</i>	c.1255-3_1255-2delCA	Acute liver failure, acute kidney injury, autism spectrum disorder	Limited Original Testing	Cerebral creatine deficiency syndrome 1 (#300352)
PMGRC-212-212-0	Other	<i>OCA2</i>	c.1465A>G, p.Asn489Asp and a complex rearrangement with deep intronic breakpoints	Oculocutaneous albinism	Limited Original Testing	Oculocutaneous albinism, type II (#203200)
PMGRC-220-220-0	Syndromic	<i>HADHB</i>	c.1390-515_1390-499del	Hypoparathyroidism, LCHAD, mitochondrial trifunctional protein deficiency, pancytopenia, bone marrow deficiency, nephrotic syndrome, tube feeding	Limited Original Testing	Mitochondrial trifunctional protein deficiency 2 (#620300) [29]
PMGRC-265-265-0	Syndromic	<i>RNF220</i>	c.1094G>A, p.Arg365Gln	Bilateral sensorineural hearing loss, leukodystrophy, seizures, mixed receptive-expressive language disorder, photoreceptor degeneration, intention tremor	New Info/Reclassification	Leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy (#619688)
PMGRC-316-316-0	Syndromic	<i>PTPN11</i>	c.794G>A, p.Arg265Gln	Short stature, gross motor delays	Limited Original Testing	Noonan syndrome 1 (#163950)
PMGRC-332-332-0	Neurodevelopmental	<i>CRPPA</i>	c.789+973C>G	Global developmental delay, hypotonia, chronic lung disease, retinopathy, severe optic atrophy, tube feeding, abnormal brain MRI	Limited Original Testing	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7 (#614643)
PMGRC-355-355-0	Neurodevelopmental	<i>TCF7L2</i>	c.1156C>T, p.Arg240Cys	Walking difficulties, unsteady gait, lateral lisps, ADHD, distal weakness, hammertoes, gynecomastia, learning disabilities	New Information/Reclassification	TCF7L2-associated syndromic neurodevelopmental disorder [30]

PMGRC-366-366-0	Neurodevelopmental	<i>DDX17</i>	c.1077G>A, p.Trp359*	Hypotonia, global developmental delay, gross motor delay, mixed receptive-expressive language disorder, foot drop, steppage gait, pes planus, ataxic gait	New Information/Reclassification	DDX17-associated neurodevelopmental disorder [31]
PMGRC-388-388-0	Syndromic	<i>RNU4-2</i>	n.64_65insT	Global developmental delay, hemiparesis, microcephaly, tube feeding, growth delays, truncal hypotonia, autism spectrum disorder, nonverbal, speech apraxia, sensory processing difficulties, abnormal brain MRI	Limited Original Testing	ReNU syndrome (#620851)
PMGRC-392-392-0	Neurodevelopmental	<i>COQ4</i>	c.718C>T, p.Arg240Cys c.202+4A>C	Spastic diplegia, gross motor delays, speech articulation delay, unsteady gait, walking difficulties	New Information/Reclassification	Spastic ataxia 10, (#620666)
PMGRC-403-403-0	Syndromic	<i>PEX1</i>	c.1359+601A>G	Zellweger Spectrum Disorder, elevated very long-chain fatty acids, decreased plasmalogen	Limited Original Testing	Peroxisome biogenesis disorder 1A (#214100)
PMGRC-418-418-0	Neurodevelopmental	<i>ZIC2</i>	c.1030_1032del, p.Trp359*	Alobar holoprosencephaly	Limited Original Testing	Holoprosencephaly 5 (#609637)
PMGRC-437-437-0	Syndromic	<i>GLI2</i>	c.1111_1120del, p.Ile371fs	Septopreoptic holoprosencephaly, solitary median maxillary incisor syndrome, low thyroid, underdeveloped pituitary, sensory processing disorder, failure to thrive	Limited Original Testing	Holoprosencephaly 9 (#610829)
PMGRC-440-440-0	Syndromic	<i>ZIC2</i>	c.1013del, p.Pro338fs	Deafness, cerebral palsy, holoprosencephaly	Previous testing information not provided	Holoprosencephaly 5 (#609637)
PMGRC-451-451-0	Syndromic	<i>ZIC2</i>	c.1377_1406dup, p.Ala461_Ala470dup	Semilobar holoprosencephaly, diabetes insipidus, delayed development	Limited Original Testing	Holoprosencephaly 5 (#609637)
PMGRC-509-509-0	Syndromic	<i>RNU4-2</i>	n.64_65insT	Microcephaly, hypotonia, delayed myelination, gross motor delay, brachycephaly, abnormal brain MRI, global developmental delay	Limited Original Testing	ReNU syndrome (#620851)
PMGRC-538-538-0	Syndromic	<i>AGO2</i>	c.602G>T, p.Gly201Val	Hip dysplasia, congenital hypotonia, cleft palate, global developmental delay, hearing loss, Pierre Robin sequence, seizures, speech delay, cerebral palsy,	New Information/Reclassification	Lessel-Kreienkamp syndrome (#619149)

				scoliosis, congenital heart defects, dysmorphic facial features		
PMGRC-540-540-0	Syndromic	<i>KMT2C</i>	c.5668C>T, p.Arg1890*	Hypotonia, fine motor delay, gross motor delay, sensory processing disorder, speech delay, decreased oral tone, selective mutism, ADHD, developmental coordination disorder, dysmorphic facial features	Limited Original Testing	Kleefstra syndrome 2 (#617768)
PMGRC-569-569-0	Neurodevelopmental	<i>STAG2</i>	87kb deletion of chrX:123,946,386-124,003590 Exon 1-4 deletion	Holoprosencephaly, global developmental delay, scoliosis, apraxia of speech, vision problems, vertebral anomaly	Previously Known	Holoprosencephaly -13, X-linked (#301043)
PMGRC-599-599-0	Neurodevelopmental	<i>RNU4-2</i>	n.69C>T	Small for gestational age, abnormal visual development/eye movement irregularity, global developmental delay, hypotonia, abnormal brain MRI	Limited Original Testing	ReNU syndrome (#620851)
PMGRC-635-635-0	Syndromic	<i>CDK13</i>	c.425dup, p.Leu143fs	Congenital heart disease, dysmorphic facial features, short stature, ADHD, global developmental delay	New Information/Reclassification	Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (#617360)
PMGRC-658-658-0	Syndromic	<i>DBT</i>	c.1282-4218G>A	Prenatal diagnosis of Argininosuccinic acid lyase deficiency and thiamine-responsive maple syrup urine disease	Limited Original Testing	Argininosuccinic aciduria, Maple syrup urine disease, type II (#620699)
PMGRC-677-677-0	Syndromic	<i>TPM3</i>	c.835C>G, p.Leu279Val	Pierre Robin sequence, tube feeding, gastroparesis, mannose-binding lectin deficiency, recurrent aspiration pneumonia and sinusitis, abnormal brain MRI, hypotonia	Limited Original Testing	Congenital Myopathy 4A, Autosomal Dominant (#255310)
PMGRC-700-700-0	Syndromic	<i>OFD1</i>	c.2413dup, p.Gln805fs	Semilobar holoprosencephaly, cleft lip and palate, bilateral postaxial polydactyly of hands and feet, bilateral cryptorchidism, Dandy-Walker malformation, ventriculomegaly, hypotelorism, seizures	Limited Original Testing	Joubert syndrome 10 (#300804)

PMGRC-753-753-0	Syndromic	<i>MSL2</i>	c.535G>T, p.Glu179*	Gross motor delay, speech delay, hypotonia, microcephaly, frontal bossing, fine hair, ptosis, pectus excavatum, low muscle tone, Mongolian spot in lower back, global developmental delay	New Information/Reclassification	Karayol-Borroto-Haghshenas neurodevelopmental syndrome (#620985)
PMGRC-812-812-0	Syndromic	<i>NDST1</i>	c.1850 C>T, p.Thr617Ile	Ankyloglossia, gross motor delays, thoracolumbar kyphosis, global developmental delay, axial hypotonia	New Information/Reclassification	Intellectual Developmental Disorder, Autosomal Recessive 46 (#616116)
PMGRC-817-817-0	Syndromic	<i>MT-TL1</i>	n.14A>G (m.3243A>G)	Fatigue, headache, recurrent fever, tinnitus, recurrent episodes of infection, sudden loss of hearing	Limited Original Testing	Diabetes-deafness syndrome (#520000)
PMGRC-890-890-0	Cardiovascular	<i>TNN</i>	c.59604_59607delAAAAG p.Gly19871fs	Dilated Cardiomyopathy	Limited Original Testing	Dilated Cardiomyopathy, 1G (#604145)
PMGRC-897-897-0	Cardiovascular	<i>SCN5A</i>	c.3911C>T, p.Thr1304Met	Dilated Cardiomyopathy	Previously Known	Dilated Cardiomyopathy, 1E (#601154)
PMGRC-904-904-0	Cardiovascular	<i>DMD</i>	c.9851G>A, p.Trp3284*	Dilated Cardiomyopathy	Previously Known	Dilated Cardiomyopathy, 3B (#302045)
PMGRC-911-911-0	Cardiovascular	<i>MYH6</i>	c.2489C>T, p.Pro830Leu	Dilated Cardiomyopathy	Limited Original Testing	Dilated Cardiomyopathy, 1EE (#613252)
PMGRC-914-914-0	Cardiovascular	<i>TNNT2</i>	c.517C>T, p.Arg173Trp	Dilated Cardiomyopathy	Limited Original Testing	Dilated Cardiomyopathy, 1D (#601494)
PMGRC-917-917-0	Cardiovascular	<i>RBM20</i>	c.2497dupA, p.Arg833fs	Dilated Cardiomyopathy	Limited Original Testing	Dilated Cardiomyopathy, 1DD (#613172)
PMGRC-921-921-0	Cardiovascular	<i>TNNI3K</i>	c.2302G>A, p.Glu768Lys	Dilated Cardiomyopathy	Limited Original Testing	Cardiac conduction disease with or without dilated cardiomyopathy (#616117)

PMGRC-991-991-0	Connective tissue & Musculoskeletal disorders	<i>TGFBR1</i>	c.1355del, p.Pro452fs	Thoracic aortic aneurysm, Aortic dissection	Previous testing information not provided	Loeys-Dietz syndrome 1 (#609192)
PMGRC-1040-1040-0	Connective tissue & Musculoskeletal disorders	<i>FBNI</i>	c.4096G>A, p.Glu1366Lys	Thoracic aortic aneurysm, Aortic dissection	Previous testing information not provided	Marfan syndrome (#154700)
PMGRC-1091-1091-0	Syndromic	<i>CREBBP</i>	exon 2 deletion	Failure to thrive, global developmental delay, pectus excavatum, axial hypotonia, abnormal brain MRI, dysmorphic features	Limited Original Testing	Rubinstein-Taybi syndrome 1 (#180849)

359 *ADHD* attention deficit hyperactivity disorder, *LCHAD* long-chain 3-hydroxyacyl-CoA dehydrogenase enzyme deficiency, *MRI*
 360 magnetic resonance imaging

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378 Supplemental Table 2. Candidate genes identified in unsolved cases. All genes are deposited in
379 GeneMatcher.

Participant ID	Candidate Gene	Variant
PMGRC-86-86-0	<i>NRXN2</i>	c.2107G>A, p.Gly703Ser
PMGRC-104-104-0	<i>GALNT16</i>	c.502+1G>A
PMGRC-116-116-0	<i>ARHGAP21; PDPK1</i>	c.3692_3693del; c.1588G>A, p.Gly530Arg
PMGRC-137-137-0	<i>CSMD3</i>	c.3158dup, p.Arg1530*
PMGRC-217-217-0	<i>SLC16A13; HIVEP1; MHY7</i>	c.410G>A, p.Arg137Gln, c.395A>G, p.Tyr132Cys; c.6212dupA, p.Tyr2071*; c.4187G>T, p.Arg1396Leu
PMGRC-239-239-0	<i>FGD5</i>	c.3372_3373del, p.Gly1125Glufs*54
PMGRC-255-255-0	<i>NRXN2; STRN3</i>	c.2605C>T, p.Arg869Trp; c.1875C>A, p.Tyr625*
PMGRC-279-279-0	<i>VWA3B</i>	c.59G>T, p.Gly20Val c.1737+1G>A
PMGRC-291-291-0	<i>NSL1</i>	c.314-2_315delAGAT
PMGRC-312-312-0	<i>TJPI</i>	c.3927-2_3927-1del
PMGRC-363-363-0	<i>CEP350</i>	c.2258del, p.Gly753Glufs*11
PMGRC-423-423-0	<i>FAM193A; MEX3D; CLPTM1</i>	c.1390-2A>G; c.595+1G>C; c.953A>G, p.Tyr318Cys
PMGRC-446-446-0	<i>TP53BP2</i>	c.40G>A, p.Val14Met c.3240del, p.Asp1080Glufs*5
PMGRC-485-485-0	<i>HEATR1; PRR30</i>	c.3613C>T, p.Gln1205*; c.275del, p.Pro92Glnfs*33, c.- 365-6C>T
PMGRC-525-525-0	<i>PLXNC1</i>	c.416del, p.Leu139Argfs*4
PMGRC-746-746-0	<i>DOPIA; PCDH9</i>	c.3559dup, p.Ile1187Asnfs*5; c.3291del, p.Ser1098Leufs*25

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

PMGRC-772-772-0	<i>MUC5B</i>	c.15477+1G>C
PMGRC-782-782-0	<i>CD177</i>	c.99G>A, p.Trp33*
PMGRC-832-832-0	<i>TLN2; IL9</i>	c.4645C>T, p.Asp1549Tyr; c.183+6T>C, p.Ser893Arg, c.202T>C, p.Cys68Arg
PMGRC-949-949-0	<i>GNRH2</i>	c.213_214insTGTC
PMGRC-985-985-0	<i>FMNL1</i>	c.1379del, p.Pro460Glnfs*19
PMGRC-992-992-0	<i>PRR14L</i>	c.4166del, p.Tyr318Cys
PMGRC-999-999-0	<i>SLC17A9</i>	c.287C>G, p.Tyr132Cys
PMGRC-1017-1017-0	<i>NXF3</i>	c.1231G>T, p.Glu411*
PMGRC-1030-1030-0	<i>CORO1C</i>	c.474G>A, p.Trp158*
PMGRC-1048-1048-0	<i>NEURL4</i>	c.1606G>T, p.Glu536*
PMGRC-1050-1050-0	<i>CUL1</i>	c.571_575del, p.Arg191Trpfs*2

380

381

382

383

384

385


386

387

388

389

390




391

392 **Figure 1. (A), (B)** Sex and race distribution of probands that underwent genome sequencing.

393

394




395

396 **Figure 2. (A)** Family structures corresponding to the participants **(B)**. Trio/Trio+ had the highest
397 diagnostic yield (21%) whereas Duo/Duo+ and Proband only families reached a diagnostic yield of 13%
398 and 10% respectively ($p = 0.03$, chi-square test).

399

400




401

402 **Figure 3. (A)** Types of prior testing undergone by participants that were deemed solved or probably
 403 solved. **(B)** Reasons diagnosis was previously missed on clinical genetic testing. Limited original testing
 404 includes gene panels that lacked the causative gene or did not detect the causative variant due to its
 405 location in a genomic region not covered by the test.

406

407




408

409 **Figure 4. (A)** RNA sequencing reads visualized with sashimi plot to indicate splicing events showing the
 410 cryptic splice inclusion in *DBT* in the proband (PMGRC-658-658-0) and the affected sibling as a result of

411 a deep (-4230) homozygous intronic single nucleotide variant. **(B-E) Mini-gene splicing assay for the**
412 ***DBT* c.1282-4218G>A variant. B)** Reference and c.1282-4218G>A variant *DBT* intron 10 fragments
413 were cloned into a mini-gene split *GFP* construct, in which N and C-terminal parts of the *GFP* gene were
414 separated by *SMN1* introns 7 and 8 (NM_000344). The construct was expressed in HEK293 cells for 48
415 hours followed by mRNA extraction, cDNA generation and NGS amplicon sequencing. Black arrows on
416 the construct image indicate primer placement. **C)** RT-PCR gel electrophoresis demonstrates inclusion of
417 the cryptic exon in both the wild type and reference transcript. **D)** Sashimi plots of reference and variant
418 hybrid *DBT*-*GFP* constructs demonstrating a preferential cryptic exon (10B) inclusion in the sequences
419 containing the c.1282-4218G>A variant. **E)** Inclusion of cryptic exon 10B leads to a premature stop
420 codon at the end of the exon, which most likely escapes nonsense-mediated decay and leads to a truncated
421 protein with a C-terminus different by 16-residues.

422



423

424 **Figure 5.** (A) The solve rate for syndromic versus non-syndromic cases. (B) The solve rate stratified by
425 phenotypic category for the non-syndromic cases.

426

427

428

429

430

431

432

433

434

435
436
437
438
439
440
441

References

- 442 1. Slavotinek, A., et al., *Diagnostic yield of pediatric and prenatal exome sequencing in a diverse*
443 *population*. NPJ Genom Med, 2023. **8**(1): p. 10.
- 444 2. Wilke, M., et al., *Diagnostic yield of exome and genome sequencing after non-diagnostic multi-*
445 *gene panels in patients with single-system diseases*. Orphanet J Rare Dis, 2024. **19**(1): p. 216.
- 446 3. Jaganathan, K., et al., *Predicting Splicing from Primary Sequence with Deep Learning*. Cell, 2019.
447 **176**(3): p. 535-548 e24.
- 448 4. Zeng, T. and Y.I. Li, *Predicting RNA splicing from DNA sequence using Pangolin*. Genome Biol,
449 2022. **23**(1): p. 103.
- 450 5. Savage, S.K., et al., *Using a chat-based informed consent tool in large-scale genomic research*. J
451 Am Med Inform Assoc, 2024. **31**(2): p. 472-478.
- 452 6. Berger, S.I., et al., *Increased diagnostic yield from negative whole genome-slice panels using*
453 *automated reanalysis*. Clin Genet, 2023. **104**(3): p. 377-383.
- 454 7. Li, H., *Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM*. 2013:
455 arXiv.
- 456 8. Poplin, R., et al., *A universal SNP and small-indel variant caller using deep neural networks*. Nat
457 Biotechnol, 2018. **36**(10): p. 983-987.
- 458 9. Chen, X., et al., *Manta: rapid detection of structural variants and indels for germline and cancer*
459 *sequencing applications*. Bioinformatics, 2016. **32**(8): p. 1220-2.
- 460 10. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner*. Bioinformatics, 2013. **29**(1): p. 15-21.
- 461 11. Robinson, J.T., et al., *igv.js: an embeddable JavaScript implementation of the Integrative*
462 *Genomics Viewer (IGV)*. Bioinformatics, 2023. **39**(1).
- 463 12. Robinson, J.T., et al., *Variant Review with the Integrative Genomics Viewer*. Cancer Res, 2017.
464 **77**(21): p. e31-e34.
- 465 13. Robinson, J.T., et al., *Integrative genomics viewer*. Nat Biotechnol, 2011. **29**(1): p. 24-6.
- 466 14. Thorvaldsdottir, H., J.T. Robinson, and J.P. Mesirov, *Integrative Genomics Viewer (IGV): high-*
467 *performance genomics data visualization and exploration*. Brief Bioinform, 2013. **14**(2): p. 178-
468 92.
- 469 15. Scott, H.A., et al., *A high throughput splicing assay to investigate the effect of variants of*
470 *unknown significance on exon inclusion*. medRxiv, 2023: p. 2022.11.30.22282952.
- 471 16. Dobin, A. and T.R. Gingeras, *Optimizing RNA-Seq Mapping with STAR*. Methods Mol Biol, 2016.
472 **1415**: p. 245-62.
- 473 17. Clark, M.M., et al., *Diagnosis of genetic diseases in seriously ill children by rapid whole-genome*
474 *sequencing and automated phenotyping and interpretation*. Sci Transl Med, 2019. **11**(489).
- 475 18. O'Brien, T.D., et al., *Artificial intelligence (AI)-assisted exome reanalysis greatly aids in the*
476 *identification of new positive cases and reduces analysis time in a clinical diagnostic laboratory*.
477 Genet Med, 2022. **24**(1): p. 192-200.

- 478 19. Negi, S., et al., *Advancing long-read nanopore genome assembly and accurate variant calling for*
479 *rare disease detection*. medRxiv, 2024.
- 480 20. Chen, Y., et al., *De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental*
481 *syndrome*. Nature, 2024. **632**(8026): p. 832-840.
- 482 21. Nguyen, T.H., et al., *The architecture of the spliceosomal U4/U6.U5 tri-snRNP*. Nature, 2015.
483 **523**(7558): p. 47-52.
- 484 22. Ganesh, V.S., et al., *Novel syndromic neurodevelopmental disorder caused by de novo deletion of*
485 *CHASERR, a long noncoding RNA*. medRxiv, 2024.
- 486 23. Wojcik, M.H., et al., *Genome Sequencing for Diagnosing Rare Diseases*. N Engl J Med, 2024.
487 **390**(21): p. 1985-1997.
- 488 24. Palmer, E.E., et al., *Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome*
489 *Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies*. Neurology, 2021.
490 **96**(13): p. e1770-e1782.
- 491 25. Alfares, A., et al., *Whole-genome sequencing offers additional but limited clinical utility*
492 *compared with reanalysis of whole-exome sequencing*. Genet Med, 2018. **20**(11): p. 1328-1333.
- 493 26. Wojcik, M.H., et al., *Beyond the exome: What's next in diagnostic testing for Mendelian*
494 *conditions*. Am J Hum Genet, 2023. **110**(8): p. 1229-1248.
- 495 27. Liu, Z., et al., *Hemizygous variants in protein phosphatase 1 regulatory subunit 3F (PPP1R3F) are*
496 *associated with a neurodevelopmental disorder characterized by developmental delay,*
497 *intellectual disability and autistic features*. Hum Mol Genet, 2023. **32**(20): p. 2981-2995.
- 498 28. Dzinovic, I., et al., *Variant recurrence confirms the existence of a FBXO31-related spastic-dystonic*
499 *cerebral palsy syndrome*. Ann Clin Transl Neurol, 2021. **8**(4): p. 951-955.
- 500 29. Thomas Cassini, S.S., Molly Behan, Cynthia J. Tift, May Christine Malicdan, David R. Adams,
501 Undiagnosed Diseases Network, Sun-Young Ahn, Debra S. Regier, *Mitochondrial trifunctional*
502 *protein deficiency caused by a deep intronic deletion leading to aberrant splicing*. JIMD Reports,
503 2024. **66**(1).
- 504 30. Dias, C., et al., *De novo variants in TCF7L2 are associated with a syndromic neurodevelopmental*
505 *disorder*. Am J Med Genet A, 2021. **185**(8): p. 2384-2390.
- 506 31. Seaby, E.G., et al., *Monoallelic de novo variants in DDX17 cause a neurodevelopmental disorder*.
507 Brain, 2024.

508

509